{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Number of patients in Phase I cohort 3 experiencing dose-limiting toxicity at the 4 milligram dose for participants within the third dose cohort","groups":[{"description":"Pomalidomide dexamethasone\n\nPomalidomide: Cohort 1 = 2 mg/day, Cohort 2 = 3 mg/day, Cohort 3 = 4 mg/day: Days 1-28\n\nDexamethasone: 10-20 mg on days 1, 8, 15, and 22","id":"OG000","title":"Pom Plus Dex"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"One month","title":"Assessing Dose-limiting Toxicity to Determine Maximal Tolerated Dosage at 4 Milligram Dose","type":"PRIMARY","unitOfMeasure":"Participants"}